Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Song, Yemei; Hu, Lei; Shu, Qiang; Ye, Jing; Liang, Jianfeng; Chen, Xi; Tan, Linhua

doi:10.1016/j.ijid.2018.08.007

Cited by 11 publications

(23 citation statements)

References 43 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on the efficacy of tigecycline in children are not prospective due to safety concerns but contain data from limited cases in which it was used as salvage therapy. [10][11][12][13][14] The FDA and European Medicines Agency have issued warnings regarding the use of tigecycline in children over 8 years of age. Acinetobacter species to carbapenem decreased to 6.2% from 2010 to 2017, and that to tigecycline was >80%.…”

Section: Discussionmentioning

confidence: 99%

“…Paediatric patients who received tigecycline for at least 2 days (at least four doses) were analysed. [10][11][12][13][14]…”

Section: Study Participantsmentioning

confidence: 99%

“…However, tigecycline can be used as a salvage treatment in children when options are limited. [9][10][11][12][13][14][15] Because pharmacokinetic safety and efficacy data are not available for children, clinical trials are required to identify the most appropriate therapeutic strategies. We present our experience with the use of tigecycline in critically ill children to guide future studies.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical and laboratory responses to tigecycline in children

Aslan

Kılıç

Kıral

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective The frequency of multidrug‐resistant bacterial infections is increasing worldwide. Tigecycline may be an important option for children with life‐threatening nosocomial infections due to multidrug‐resistant bacteria. However, there are few published data on the use of tigecycline in paediatric patients. By examining the results of tigecycline use in children, we aimed to draw attention to the fact that tigecycline may be an alternative in the treatment of resistant infections in children. Methods Paediatric patients treated with tigecycline from 1 January 2010 to 31 October 2018 at Eskişehir Osmangazi University Medical Faculty, which is a tertiary hospital, were analysed retrospectively to assess the efficacy and safety of tigecycline treatment in children. Patients using tigecycline were identified using the pharmacy database. Clinical and laboratory data were obtained from the files. Results and discussion This study included 91 children aged 7 months to 17.5 years; 52 were female (57.1%). At least one predisposing factor was present in 98.9% of the patients. Fifty‐one bacteria were isolated from 44 patients. The tigecycline resistance rate was 3.9%. Only 2 of 91 patients experienced one or more side effects of tigecycline. Tigecycline can be used as salvage therapy in resistant infections where options are limited, although definitive conclusions about the efficacy and safety of tigecycline in children cannot be reached. What is new and conclusion Tigecycline may be a safe and important option in paediatric nosocomial infections due to resistant bacteria. Resistant bacterial infections have become more common in recent years, its treatment becomes a difficult problem. Tigecycline has a broad‐spectrum antibacterial activity including resistant pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Paediatric patients who received tigecycline for at least 2 days (at least four doses) were analysed. [10][11][12][13][14]…”

Section: Study Participantsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical and laboratory responses to tigecycline in children

Aslan

Kılıç

Kıral

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…Tigecycline was used for managing bacteremia, pneumonia, and three unspecified infections. Song et al [ 4 ] described a case series of 22 pediatric patients suffering from serious infections after surgery with median age of 7.5 months who received an initial dose of 1.5 mg/kg and then 1.2 mg/kg of tigecycline every 12 h. Median duration of treatment was 17 days and 86% of patients had positive response. Emiroglu et al [ 14 ] described a 5-month-old infant with ventriculo-peritoneal shunt meningitis.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years the growing drug resistance in nosocomial gram-negative bacteria has resulted in treatment challenges for physicians, mostly for pediatricians [1,2]. Despite the rising relevance of Pseudomonas aeruginosa infections in adults, only a few studies have evaluated this condition in pediatric population [3,4]. This case report describes the efficacy and safety of glycylcycline antibiotic tigecycline as a salvage therapy for an infant with severe sepsis caused by multi-drug-resistant Pseudomonas aeruginosa.…”

Section: Introductionmentioning

confidence: 99%

Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report

Krasnanova

Kováčiková

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Sepsis is the leading cause of death in infants and children worldwide. The growing drug resistance in nosocomial gram-negative bacteria has resulted in treatment challenges. One of the most common multi-drug-resistant bacteria is Pseudomonas aeruginosa. Resistance to antibiotics used in Pseudomonas aeruginosa infections limits the therapeutic options. We present a tigecycline administration in a 5-month-old infant with patent arterial duct, heart failure, and respiratory failure due to respiratory syncytial virus bronchiolitis with subsequent respiratory distress syndrome and severe sepsis caused by multi-drug-resistant Pseudomonas aeruginosa. Despite combined antibiotic therapy with meropenem, amikacin, and colistin, inflammatory markers increased. Because of life-threatening condition, tigecycline was added to the therapy and was administered intravenously twice daily. Within 48 h, inflammatory markers started to decrease and tigecycline therapy continued for 13 days without adverse effects. Tigecycline used in combination with other antibiotics might be a valuable therapeutic approach in the management of multidrug-resistant bacteria infections in pediatric patients when conventional antibiotics have failed. Further studies are needed to evaluate the efficacy and safety of tigecycline administration in critically ill pediatric patients.

show abstract

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Yaghoubi

Zekiy

Krutova

et al. 2021

Eur J Clin Microbiol Infect Dis

135

View full text Add to dashboard Cite

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Abstract: Tigecycline salvage therapy was successful in 86% of critically ill pediatric patients with MDR/XDR infections after surgery, with no severe adverse effects.

Cited by 11 publications

References 43 publications

Clinical and laboratory responses to tigecycline in children

Clinical and laboratory responses to tigecycline in children

Tigecycline Therapy for Multi-drug-Resistant Pseudomonas aeruginosa Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Contact Info

Product

Resources

About